

PRESS RELEASE  
17 March 2015



## **BioInvent announces plan to initiate clinical development of TB-403 in pediatric cancer together with ThromboGenics**

**Lund, Sweden – 17 March, 2015** – BioInvent International AB (OMXS: BINV) today announces that a Phase I/IIa program with TB-403 in medulloblastoma patients is expected to be initiated during the second half of 2015. Medulloblastoma is a rare, life-threatening cancer that exclusively affects children and adolescents. The favorable safety profile of TB-403 has been demonstrated in previous clinical trials in patients with other diseases. The project is conducted in collaboration with ThromboGenics NV.

TB-403 is a humanized monoclonal antibody against placental growth factor (PlGF). PlGF is expressed in several types of cancer, including medulloblastoma. High expression of PlGF receptor neuropilin 1 has been shown to correlate with poor overall survival. Treatment with TB-403 in relevant animal models for medulloblastoma has furthermore demonstrated beneficial effects on tumour growth and survival. The antibody can potentially be used in other pediatric cancer indications, including neuroblastoma.

"We're delighted over the opportunity to develop a completely new therapy for a life-threatening form of cancer that affects children and adolescents. The development risk of the project is offset by the favorable safety profile that TB-403 demonstrated in previous trials", **says BioInvent CEO, Michael Oredsson.**

The pharmaceutical project TB-403 is conducted in collaboration with the Belgian biopharmaceutical company ThromboGenics NV. BioInvent is contributing half of the development costs and are entitled to 40 percent of all future revenues from the project.

### **To the editors:**

#### **About BioInvent**

BioInvent International AB is a research-based pharmaceutical company focused on the discovery and development of innovative antibody-based drugs against cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool, F.I.R.S.T.<sup>™</sup>, and the antibody library, n-CoDeR<sup>®</sup>, are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. BioInvent has also considerable experience in and a facility for process development and production of antibodies for clinical studies. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent with the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Servier and Xoma. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

### **For further information, please contact:**

Michael Oredsson  
President and CEO  
+46 (0)46 286 85 67  
+46 (0)707 16 89 30  
[michael.oredsson@bioinvent.com](mailto:michael.oredsson@bioinvent.com)

**BioInvent International AB (publ)**

Co. reg. No. 556537-7263

Visiting address: Sölvegatan 41

Mailing address: 223 70 LUND

Phone: +46 (0)46 286 85 50

[info@bioinvent.com](mailto:info@bioinvent.com)

[www.bioinvent.com](http://www.bioinvent.com)

*The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.*

*Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 17 March, 2015.*